NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company cited the absence of approved vaccines or therapies specifically targeting the virus strain.
NV-387's host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical, according to the company. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
The company's lead drug candidate, NV-387, is a broad-spectrum antiviral drug that NanoViricides plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles.
NanoViricides holds a worldwide exclusive perpetual license to its platform technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases, including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
The company noted that there can be no assurance that any of its pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. For more information, visit the company's newsroom at https://ibn.fm/NNVC.
The full press release is available at https://ibn.fm/aSF5Z.
